Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announces the upcoming launch of Alakin, a comprehensive healthcare management platform developed by its subsidiary Tech2Heal. This SaaS solution, built on FHIR standards, aims to improve patient engagement and optimize workflows in healthcare settings. A pilot study will commence at a 30,000-patient facility in Paris, with full deployment planned for August 2022. Alakin will streamline patient care processes, potentially leading to significant time and cost savings for healthcare providers.
Summary not available.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a finalist in the prestigious i-Nov Innovation Contest. This recognition highlights the innovative potential of its Qookka digital therapy for mental health disorders, with less than 10% of entries making the cut. The contest, backed by the Programme d'Investissements d'Avenir in France, offers up to €5M in co-financing for winners. Qookka utilizes advanced AI algorithms and digital biomarkers for enhanced patient support and monitoring.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced a marketing services agreement with Octagon Media Corp to enhance its digital media presence. The contract, lasting three months, involves monthly payments of US$25,000 and the issuance of 500,000 stock options at CAD$0.20. Additionally, the company granted 800,000 options to management at the same exercise price. Through strategic partnerships and a focus on AI and ML technologies, AI/ML aims to drive growth in the healthcare sector.
AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.
AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed a non-brokered private placement, issuing 4 million units at $0.15 per unit, resulting in $600,000 in gross proceeds. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 for 12 months. The funds will support platform deployment with healthcare clients and general operating expenses. The company incurred $25,337.81 in finder's fees for this offering.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a founding participant in the PariSanté Health Tech Campus in Paris, France. This initiative aims to foster collaboration among leading health-tech entities to enhance research and innovation in e-health. Tech2Heal's recognition reflects its leadership in digital mental healthcare. The campus includes prominent players like Inserm and Health Data Hub, providing Tech2Heal access to a rich ecosystem of expertise to strengthen its healthcare solutions.
AI/ML Innovations Inc. announces that its subsidiary, Health Gauge, has received a patent (US Patent No. 11183303) for its wearable health monitoring technology. This technology utilizes machine learning to enhance the accuracy of health metrics such as blood pressure, enabling users to achieve personal health goals. Key features include predictive health analysis and behavioral insights based on data from various bio-signals. The patent solidifies Health Gauge's position in the AI-supported telemedicine field, aimed at improving health monitoring during and beyond the pandemic.
AI/ML Innovations (CSE:AIML)(OTCQB:AIMLF) announces a SaaS licensing agreement between its subsidiary Health Gauge and Rapid Test & Trace Canada (RTTC) for a COVID-19 testing solution. Health Gauge will earn up to $2.50 per test plus additional fees. The contract grants RTTC exclusive rights in Canada, the U.S., Mexico, Australia, and the U.K., contingent upon achieving a minimum of 50,000 tests monthly per country by March 1, 2022. Deployment is expected within 30 days. This agreement is projected to generate substantial recurring revenue for Health Gauge.